6 years ago

Lunac Therapeutics Secures £2.65M Series A Funding for Advanced Anticoagulants

  • Lunac Therapeutics, a UK-based drug discovery company focused on advanced anticoagulants with minimal bleeding risk, raised £2.65 million in Series A funding

  • The round was led by Epidarex Capital and the University of Leeds

  • Lunac Therapeutics is a spin-out from the University of Leeds, targeting activated Factor XII to develop next-generation anticoagulants

  • The company believes this approach will reduce the bleeding risk associated with current therapies

  • The funding will be used to advance the development of Lunac Therapeutics' anticoagulants.

      • ProblemHealthcare

      "Current anticoagulant drugs are effective at preventing blood clots but carry a significant risk of causing bleeding."

      Solution

      "Lunac Therapeutics is developing a new class of anticoagulants that target Factor XII, a protein involved in blood clotting but not bleeding, to reduce the risk of bleeding complications."

      Covered on